Exp Clin Endocrinol Diabetes 1985; 86(5): 185-189
DOI: 10.1055/s-0029-1210485
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Effects of the New Progestagen STS 557 on the Biosynthesis of Steroids in Tissue Slices of the Human Ovary

P. Schürenkämper, K. Lisse
  • Clinic of Obstetrics and Gynaecology (Director: OMR Prof. Dr. med. habil. H. Bayer) Humboldt-University Berlin/GDR
Further Information

Publication History

1984

Publication Date:
16 July 2009 (online)

Summary

To examine the direct effect of STS 557 (17 α-oyanomethyl-17 β-hydroxy-estra-4,9-dien-3-one) on the ovarian biosynthesis of steroids, tissue slices obtained from a cyclically functional human ovary were incubated with [4-14C]-pregnenolone as precursor. The steroid production was determined by measuring the concentration of eleven 14C-labelled steroids in the medium at the end of a 3 h-incubation.

The addition of STS 557 to the incubation medium inhibited the biosynthesis of androstenedione, progesterone, 17 α-hydroxyprogesterone and oestrone, whereas dehydroepiandrosterone, 17 α-hydroxypregnenolone and Δ 5-androstenediol increased. The principal manifestation of the effect of STS 557 is the apparent inhibition (87%) of the 3β-hydroxysteroiddehydrogenase-Δ5-4-isomerase activity in this experimental model. It is noteworthy, that the effects of STS 557 are similar to those effects previously published for other clinical used progestagens and the “pure antiandrogen” cyproterone.

The results indicate, that STS 557 acts directly on the steroid biosynthesis in the human ovary in vitro.